Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oligodendroglioma.

Warren P Mason1

  • 1Department of Medicine, Princess Margaret Hospital, 610 University Avenue, Suite 18-717, Toronto, Ontario, M5G 2M9, Canada. warren.mason@uhn.on.ca.

Current Treatment Options in Neurology
|June 22, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Framework for Statistical Parametric Mapping of the Interactions between Glioblastoma Location, Treatment, Prognostic Variables, and Survival Using a Phase III Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Correction to: Nomograms for predicting survival of elderly patients with newly diagnosed glioblastoma: a secondary analysis of the CCTG CE.6 trial.

Journal of neuro-oncology·2026
Same author

Nomograms for predicting survival of elderly patients with newly diagnosed glioblastoma: a secondary analysis of the CCTG CE.6 trial.

Journal of neuro-oncology·2026
Same author

Concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma (CATNON; EORTC study 26053-22054): final and exploratory analyses of a randomised, open-label, phase 3 trial.

The Lancet. Oncology·2025
Same author

Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.

The Lancet. Oncology·2025
Same journal

Visual Impairment and Driving in Older Adults: A Narrative Review.

Current treatment options in neurology·2026
Same journal

Non-Cognitive Symptoms in Alzheimer's Disease and Their Likely Impact on Patient Outcomes. A Scoping Review.

Current treatment options in neurology·2026
Same journal

Update on the Treatment of Autonomic Disorders.

Current treatment options in neurology·2025
Same journal

Primary Progressive Aphasia Treatment: Current Treatment Options in Neurology Article Topic: Management of Primary Progressive Aphasia.

Current treatment options in neurology·2025
Same journal

Emerging Principles for Treating Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD).

Current treatment options in neurology·2025
Same journal

Diagnosis and Management of Progressive Corticobasal Syndrome.

Current treatment options in neurology·2025
See all related articles

Oligodendroglial tumors can now be reliably diagnosed using 1p/19q chromosome loss, guiding chemotherapy as a primary treatment. This approach improves outcomes and minimizes radiation side effects for brain tumor patients.

Area of Science:

  • Neuro-oncology
  • Molecular Pathology
  • Genetics

Background:

  • Oligodendroglial tumors are uncommon primary brain tumors with controversial diagnosis due to lack of specific markers.
  • Histologic classification into low-grade or anaplastic is subjective, leading to diagnostic challenges.
  • Increasing incidence may be linked to less rigorous diagnostic criteria.

Purpose of the Study:

  • To review the current management of oligodendroglial tumors.
  • To emphasize the expanding role of chemotherapy in treating these neoplasms.
  • To highlight the impact of molecular diagnostics on treatment strategies.

Main Methods:

  • Review of current literature on oligodendroglial tumor management.
  • Emphasis on molecular diagnostics, specifically 1p/19q loss of heterozygosity.

Related Experiment Videos

  • Analysis of chemotherapy and radiotherapy roles and timing.

    • Main Results:

    • Loss of heterozygosity of chromosomes 1p and 19q serves as a unique genetic signature for oligodendroglial tumors.
    • These genetic alterations correlate with predictable and durable response to chemotherapy.
    • Chemotherapy, particularly with temozolomide, is increasingly used as initial treatment, reducing reliance on radiotherapy and its late neurocognitive sequelae.

    Conclusions:

    • Molecular diagnostics have improved the reliability of oligodendroglial tumor identification.
    • Chemotherapy is becoming the preferred initial treatment for oligodendroglial tumors with favorable genetic derangements.
    • This shift in treatment strategy aims to improve patient prognosis and minimize treatment-related toxicities.